Finance

05/14/25

Writing the future of genetic medicines, with Stylus

Biotech

Finance

Science

04/03/25

Showing the math: How IRA destroys NPV

Biotech

Finance

Policy

02/04/25

Planetary Tech March Madness

Culture

Finance

Planetary

01/11/25

Semper Maior: Pumping up the candor

Biotech

Culture

Finance

12/20/24

What you were reading — Rapport’s top stories of 2024

Biotech

Culture

Finance

Policy

Science

Planetary

10/28/24

Raven-built Aliada shuttles its potential best-in-class Alzheimer’s treatment to AbbVie

Biotech

Finance

Science

08/30/24

What are smart ways boards can identify and negotiate opportunities to save money?

Finance

08/08/24

What makes a venture round a crossover round?

Biotech

Finance

07/18/24

Semper Maior: Reflecting on a quiet 1H24

Biotech

Finance

06/12/24

Discount rates and drug value: A Q&A with Josh Cohen

Finance

Policy

Biotech

05/02/24

Mariana’s acquisition:RAVen, radiopharmaceuticals, and reflections on company-building

Biotech

Finance

04/25/24

RAVen’s Project Condor fights flu with Cidara deal

Biotech

Finance

Science

04/15/24

Obvious in hindsight: On financings, pricing uncertainty, and early access to data

Biotech

Finance

02/29/24

Money talks: Your biotech compensation questions, answered

Biotech

Culture

Finance

01/05/24

Semper Maior: Spirits Rising

Biotech

Finance

10/27/23

A going concern clause isn’t always a concern

Biotech

Finance

10/20/23

Everything you’ve always wanted to ask an Audit Committee member (but were too afraid to ask)

Biotech

Finance

09/19/23

Why we’re stuck on Hyku Biosciences

Biotech

Finance

Science

08/24/23

Shutting down Silverback — a Q&A with Laura Shawver

Biotech

Finance

07/01/23

RA Capital’s 1H23 Core Biotech Report

Finance